DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General Meeting
(Thomson Reuters ONE) -
AMF REGULATED INFORMATION
Montrouge, France, June 15, 2017
DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary
General
Meeting
Shareholders approve all proposed resolutions
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT) today held its Ordinary and Extraordinary General Meeting, which was
chaired by Dr. Pierre-Henri Benhamou, Chairman & Chief Executive Officer of DBV
Technologies.
At the General Meeting, the Company's shareholders approved all resolutions
submitted by the Board of Directors. These resolutions are posted on the
Investor Relations section of the Company's website, http://www.dbv-
technologies.com/en/investor-relations.
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with
broad potential applications in immunotherapy. Viaskin is based on epicutaneous
immunotherapy, or EPIT®, DBV's method of delivering biologically active
compounds to the immune system through intact skin. With this new class of self-
administered and non-invasive product candidates, the company is dedicated to
safely transforming the care of food allergic patients, for whom there are no
approved treatments. DBV's food allergies programs include ongoing clinical
trials of Viaskin Peanut and Viaskin Milk, and preclinical development of
Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of
Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring
potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY.
Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global
Select Market in the form of American Depositary Shares (each representing one-
half of one ordinary share) (Ticker: DBVT). For more information on DBV
Technologies, please visit our website: www.dbv-technologies.com
DBV Technologies Contact
Sara Blum Sherman
Director, Investor Relations
+1 212-271-0740
sara.sherman(at)dbv-technologies.com
Media Contact
Andrea Fassacesia, Weber Shandwick
+1 212-445-8144
afassacesia(at)webershandwick.com
Media Contact Europe
Caroline Carmagnol, Alize RP, Relations Presse
+33 (0)6 64 18 99 59
caroline(at)alizerp.com
PDF version:
http://hugin.info/156437/R/2113605/804045.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 15.06.2017 - 22:30 Uhr
Sprache: Deutsch
News-ID 548266
Anzahl Zeichen: 3237
contact information:
Town:
Bagneux
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 173 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
